Celgene

Celgene Corporation
Company type	Subsidiary
Industry	Biotechnology
Founded	1986
Founder	Sol J. Barer
Headquarters	Summit, New Jersey, U.S.
Key people	Robert J. Hugin (Executive Chairman); Mark Alles (CEO)
Products	Revlimid; Abraxane; Pomalyst/Imnovid; Thalomid; Idhifa
Revenue	$15.281 billion (2018)
Net income	$4.046 billion (2018)
Total assets	$35.480 billion (2018)
Total equity	$6.161 billion (2018)
Number of employees	8,852 (2018)
Parent	Bristol Myers Squibb
Website	www.bms.com
	Footnotes / references;

Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).^[2]

^ "Celgene Corporation 2018 Form 10-K Annual Report". U.S. Securities and Exchange Commission.
^ Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company, PM BMS, November 20, 2019; retrieved May 20, 2020

[10K-1] "Celgene Corporation 2018 Form 10-K Annual Report". U.S. Securities and Exchange Commission.

[acquisition-2] Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company, PM BMS, November 20, 2019; retrieved May 20, 2020

[1]

[2]